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The mRNA-directed binding of aminoacyl-tRNA 
to the ribosome requires a special protein factor 
EF-T, and GTP. A ternary complex between amino- 
acyl-tRNA, EF-T, and GTP is formed as an inter- 
mediate from which the ~~oacyl-t~A is transfe~ed 
to the ribosomal recognition site (reviewed [11). it is 
the main feature of EF-T, that in the form of 
EF-T, .GTP it is able to discriminate between amino- 
acylated and non- or acylaminoacyfated tRNAs 
[2-4]. This provided a basis for the accumulat~g 
evidence that the 3’-terminus of aminoacyl-tRNA is 
involved in the recognition reaction between 
aminoacyl-tRNA and the elongation factor T, [S-7]. 
Therefore, we prepared two analogs of the 3’oterminus 
of phenylalanyl-tRNA, 2’(3’)0L-phenylalanyl- 
adenosine and cytidylyl-(3’ + 5’~2’(3’)U-L-p~enyl- 
alanyladenosine and tested them for the ability to 
replace aminoacyl-tRNA in protecting the aminoacyl- 
tRNA binding site of EF-T, from inactivation by 
N-tosyl-L-phenylalanylchloromethane. 
The results presented here show that: 
(1) A-Phe and CpA-Phe can interact with the amino- 
acyl-tRNA binding site of EF-T,; 
(2) The SH group in the aminoacyl-tRNA binding 
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area of EF-T, might be the component involved 
in the interaction between elongation factor T, 
and the 3’-terminus of aminoacyl-tRNA. 
2. Materials and methods 
Crystalline EF-Tu.GDP was prepared according to 
[S]. tRNA fromE. coli B was prepared by the method 
in [9]. Aminoacyl-tRNA: tRNA was charged with 8 
Lamino acids (Leu, Val, Ala, Arg, TUT, Glu, Ses, Gly) 
by the procedure in [lo] except hat each amino acid 
in the charging mixture was 0.2 mM. “C-Labelled 
TPCK of spec. act. 4.6 mCi/mmol was obtained from 
the Laboratory for Radioactive Isotopes, Czechoslovak 
Academy of Sciences, Prague. 2’(3’)-O-L-phenylalanyl- 
adenosine was prepared by the method in [ 1 1] with 
some modi~cations of the pu~~cation step. The 
synthesis of cytidylyl-(3’ + 5’)-2’(3’)0-L-phenyl- 
alanyladenosine will be described elsewhere. 
Preparation of EF-T,.GTP: 20 nmol crystalline 
EF-T,.GDP was washed with 0.4 ml solution con- 
taining 42% saturated ammonium sulphate, 20 mM 
Tris-HC!l (pH 7.6), 3 mM ma~e~urn acetate and 
5 mM 2-mercaptoethanol and 3 times with 0.35 ml 
of the same solution but with 10 @I GDP and without 
2-mercaptoethanol. The sediment of crystals was 
dissolved in 0.4 ml buffer containing 100 mM Tris- 
HCl (pH 7.6), 10 mM magnesium acetate and 100 mM 
~monium acetate. 5fi 20 mM GTP, 20 fi 0.1 M 
phosphoenolpyruvate nd 10 gg pyruvate kinase were 
added and the solution was incubated for 10 mm at 
35OC. 
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Detection of interaction between EF-T;GTP and 
aminoacyl-tRNA or the analogs of the 3’-terminus 
of aminoacyl-tRNA. The method is based on the 
ability of the compound TPCK to compete specifically 
with natural ligands for the aminoacyl-tRNA binding 
site in EF-T, [ 12-161.6 nmol EF-T;GTP (freshly 
prepared, in 130 ~1 buffer solution as above) either 
alone or in the presence of tested compounds (con- 
centrations of A-Phe and CpA-Phe corresponded to 
the actual amount of aminoacylated compound) were 
treated with 10 nmol [14C]TPCK in final vol. 155 ~1, 
if not otherwise specified. The reaction was started 
by the addition of [14C]TPCK (a methanolic solution 
of TPCK was used and the final concentration of 
methanol in the reaction mixture was -6.5%) and 
carried out at 4°C. At the time intervals indicated, 
20 ~1 portions from every incubation mixture were 
withdrawn and mixed with 5 4 methanol and 10 ~1 
0.1 M dithiothreitol for 3 min at 4°C to remove the 
free unreacted TPCK [lo]. 10 ~1 (10 mg/ml) bovine 
serum albumin and 3 ml cold 5% trichloroacetic acid 
were further added and after 20 min at 4”C, the 
TPCK incorporation into EF-T, was determined as 
the radioactivity retained in the trichloroacetic preci- 
pitate collected on Millipore nitrocellulose filters 
which were washed with 10 ml cold 5% trichloroacetic 
acid and dried. The radioactivity was measured in a 
methane-flow windowless Frieseke-Hoepfner counter. 
3 100 cpm correspond to 1 nmol TPCK incorporated. 
Blank samples containing the same components except 
EF-T,.GTP were treated in the same way as the 
whole systems and run simultaneously. The radio- 
activity retained in Millipore filters under these condi- 
tions (300-400 cpm) was subtracted from the values 
obtained for the complete systems. The protein con- 
centration was determined by the method in [ 171. 
3. Results 
We employed an irreversible inhibitor of elongation 
factor T,, N-tosyl-L-phenylalanyl chloromethane 
[18,19] to detect the interaction of the factor with 
the respective ligands for its aminoacyl-tRNA binding 
site. TPCK destroys the ability of EF-T,.GTP to form 
the ternary complex with aminoacyl-tRNA [ 13,141 
because it reacts specifically with the SH group of 
EF-T, which is essential for the interaction of the 
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factor with aminoacyl-tRNA [ 15,20,2 11. On the 
other hand,it is possible to show with the radioactively- 
labelled TPCK that a prior binding of aminoacyl- 
tRNA to EF-T,.GTP protects the protein from TPCK 
incorporation (fig.1 ; cf. [ 15 ,161) and this suggests 
that both components, i.e., aminoacyl-tRNA and 
TPCK, compete for the same binding site in EF-T,. 
Deaminoacylated tRNA, which is not able to form a 
complex with EF-T,.GTP, also has no effect on the 
incorporation of TPCK (fig.l), thus illustrating the 
specificity of the competition reaction. 
If the 3’-end of aminoacyl-tRNA is involved in the 
binding reaction with EF-T,, then it could be expected 
that this portion of the molecule of aminoacyl-tRNA 
alone should protect the factor from TPCK incorpora- 
tion. Therefore, we prepared A-Phe and CpA-Phe as 
simple analogs of the 3’end of aminoacyl-tRNA and 
tested them for the ability to prevent the reaction 
between TPCK and EF-T, (fig.2, table 1). It is evident 
that both CpA-Phe and even A-Phe protect EF-T,.GTP 
against TPCK incorporation as does the whole mole- 
cule of aminoacyl-tRNA. In contrast, adenosine or 
an equimolar mixture of adenosine and phenylalanine 
(at 1 mM, data not shown) do not prevent the reaction 
between the factor and TPCK. Puromycin, which 
possesses the aminoacyl residue linked to the dimethyl- 
adenosine moiety of the molecule by an amide bond, 
instead of a natural ester bond, does not affect the 
4 
+ aminoacyl-tRNA 
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timehoun) 
Fig.1. Protection of EF-Tu.GTP against TPCK incorporation 
by aminoacylated tRNA. Detection of interaction between 
EF-Tu.GTP and aminoacyl-tRNA was determined as in 
section 2. (o) EF-T,.GTP, (a) EF-T,GTP + tRNA (160 cc&, 
(0) EF-T,.GTP + aminoacyl-tRNA (160 rg). 
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Fig.2 Protection of EF-TuGTP against TPCK incorporation 
by A-Phe and CpA-Phe. Detection of interaction between 
EF-TuGTP and the analogs of the 3’-terminus of amino- 
acyl-tRNA was determined as in section 2. (0) EF-TuGTP, 
(O)FF-TuGTP + 3.4 mM adenosine, (o) EF-Tu+GTP + 
1 mM puromycin, (0) EF-TuGTP f 3.4 mM A-Phe, (A) 
EF-TuGTP + 1 mM CpA-Pbe. 
rate of in~o~oration of TPCK into EF-T,+GTP either 
(fig.2). 
From a comparison of the results presented in 
fig.2 and table 1 it is obvious that pheny~alany~di- 
nucleoside phosphate ismore effective in protection 
of EF-T, than simpler phenylalanyladenosine. Under 
Table 1 
Lnteraction of A-Phe and CPA-Phe with EF-Tu.GTP 
Addition to EF-TuGTP % TPCK incorp. 
- 
None 100 
Ado {IO-” M) 94 
A-Phe (4 x LO-’ M) 65 
(8 x LO-’ M) 54 
(1.6 X IO-3 M) 3.5 
CpA-Phe (8 X 10-s M) 75 
(4 x W4 M) 28 
(8 x lo-’ M) 20 
1.2 nmol EF-Tu.GTP (in 20 ~1 buffer solution prepared as in 
section 2), either alone or in the presence of adenosine or 
A-Phe or CpA-Phe (at concentrations indicated) were treated 
with 2.1 nmol [ WJTPCK in methanol in final ~0125 rl. 
After 30 min at 4”C!, dithio~reitol and methanol were added 
to stop the reaction, and TPCK incorporation was deter- 
mined as in section 2.100% incorporation of TPCK corre- 
sponds to 1420 cpm 
the experimental conditions employed, 50% shielding 
of EF-T,GTP against TPCK is observed with about 
2 X 10b4M CpA-Phe or 8 X IO-‘M A=Phe (table 1). 
4. Discussion 
In f 15 ,I 61, we have shown that the compound, 
N-tosyl-L-phenylalanyl chloromethane, can be used as 
a site-directed inhibitor of the elongation factor T, 
for the specific labe~ng in its am~oacyl-tRNA 
b~d~g site. ~inoacyl-tea, the natural ligand of 
EF-T,.GTP whose binding to the factor is prevented 
by the inhibitor, was in turn found to protect he 
protein from ~~orporation of the radioactive TPCK. 
We tried to determine which part of the molecule of 
aminoacyl-tRNA was responsible for this activity, i.e., 
could participate in the interaction with EF-T,. The 
findings that only the ~~oacylated in contrast o 
deaminoacylated tRNA was active in the protection 
of EF-T,.GTP against TPCK and other evidence 
]2-‘71 strongly suggested that especially the 3’-termi- 
nus of aminoacyl-tea could have been involved. To 
test this idea, we used two fragments of the 3’end of 
phenylalanyl-tRNA, CpA-Phe and A-Phe, as analogs 
of this end of am~oacyl-tea and assayed them in 
our system with TPCK. 
As shown in section 3, both tested fragments 
protect the elongation factor from incorporation of 
the ~~bitor as does the whole molecule of aminoacyl- 
tR.NA. This indicates that A-Phe and CpA-Phe can 
interact with EF-T,sGTP. 
The presence of an ester bond between an amino 
acid and adenosine seems to be essential for the pro- 
tective ability of the tested analogs because adenosine 
alone or in conjunction with phenylalanine does not 
affect the incorporation of TPCK into the factor. 
Similarly, puromycin which resembles very closely 
phenylahnyladenosine but whose ester bond is 
replaced by an amide bond does not produce any 
shielding effect against TPCK (fig.2). All these findings 
show that the structure of the 3’end of aminoacyl- 
tRNA is checked by EF-T,.GTP with great efficiency, 
Further, it appears that the presence of the whole 
polynucleotide molecule is not necessary for the 
recognition reaction between EF-T, and aminoacyl- 
tRNA because the observed iscrimination specificity 
of EF-T, against all 4 tested fragments of the 3’-termi- 
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nus of aminoacyl-tRNA parallels the known discri- 
mination ability of EF-T,.GTP against the structure 
of this area in the intact molecule of aminoacyl4RNA. 
We have shown here that neither adenos~e alone, just 
as de~~oa~ylated tRNA f2-41, nor puromycin, 
just as aminoacyl-tRNA in which the ester bond 
normally linking the amino acid to tRNA is replaced 
by an amide bond [7], are sufficient ligands for the 
aminoacyl-tRNA binding site in EF-T,. 
The results on protection of EF-T, against TPCK 
are in complete agreement with what we know of the 
requirements of the binding reaction between EF-T, 
and aminoacyl-tRNA. This suggests hat the assay 
with the radioactively-labelled TPCK may be alter- 
natively used as a specific and very simple system for 
the detection of interaction of EF-T, with aminoacyl- 
tRNA and with ligands for its aminoacyl-tRNA 
binding site. 
The present results have also confirmed the findings 
[S] that cytidylyl phenylalanyladenosine caninteract 
with EF-Tn. Moreover, we were able to show that 
even 2‘(3‘~U-L-phenyl~anyladenosine i  active. Thus, 
A-Phe appears to be the smallest known ligand for the 
aminoacyl-tRNA binding site of EF-Ty and the attach- 
ment of cytidylic acid residue to its 5 end increases 
its affinity for the factor. This supports the general 
view that the nucleotide units at the 3’4erminus of 
tRNA are somehow intimately involved in the recog 
nition and binding process between aminoacyl-tRNA 
and EF-T, [6] and gives evidence for the 3’4erminal 
aminoacyladenosine as being one of the components 
participating in this reaction. In this respect, the 
situation is rem~~cent of another am~oa~yl-tRNA 
binding site, the acceptor binding site on the ribosome .
In contrast to the ribosomal site, however,EF-T,eGTP 
discriminates between phenylalanyladenosine a d 
puromycin. 
Finally, these results provide, for the first time, 
the ~fo~ation on the localization of the binding site 
for the functionally important 3’4erminus of amino- 
acyl-tRNA in the molecule of EF-T,. We have shown 
that A-Phe and CpA-Phe prevent the reaction between 
TPCK and the SH group of EF-T, essential for the 
binding with aminoacyl-tRNA. It can, therefore, be 
concluded that the SH group in the a~oacyl-tRNA 
binding area of the factor might be involved in the 
interaction between elongation factor T, and the 
3’4erminus of amincacyl-tRNA. 
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